Notably, corticosteroids are under evaluation and in clinical use as a treatment for COVID-19 infections primarily due to their role in the reduced expression of the angiotensin-converting enzyme 2 (ACE2).5 In this meta-analysis, we aim to analyze mortality outcomes in cardiovascular disease (CVD) patients and groups receiving corticosteroids therapy, intensive care admission status during COVID-19 hospitalization and groups receiving corticosteroid therapy, and lastly, mortality outcomes in mechanically ventilated patients. The gene discussed is ACE2; the disease is COVID-19.